Nafziger AN - Search Results

1

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.

Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS Jr, Nafziger AN, Ma JD. Yang J, et al. Among authors: nafziger an. J Clin Pharmacol. 2018 Sep;58(9):1205-1213. doi: 10.1002/jcph.1125. Epub 2018 Apr 17. J Clin Pharmacol. 2018. PMID: 29663428

2

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Kim JS, et al. Among authors: nafziger an. J Clin Pharmacol. 2002 Apr;42(4):376-82. J Clin Pharmacol. 2002. PMID: 11936561

3

Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.

Ma JD, Nafziger AN, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. J Clin Pharmacol. 2004 May;44(5):447-56. doi: 10.1177/0091270004264642. J Clin Pharmacol. 2004. PMID: 15102864

4

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.

Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. J Clin Pharmacol. 2004 Jun;44(6):570-6. doi: 10.1177/0091270004265366. J Clin Pharmacol. 2004. PMID: 15145963

5

The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.

Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. J Clin Pharmacol. 2006 Jan;46(1):103-8. doi: 10.1177/0091270005283286. J Clin Pharmacol. 2006. PMID: 16397289 Clinical Trial.

6

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.

Lee LS, Bertino JS Jr, Nafziger AN. Lee LS, et al. Among authors: nafziger an. J Clin Pharmacol. 2006 Feb;46(2):229-34. doi: 10.1177/0091270005283466. J Clin Pharmacol. 2006. PMID: 16432275 Clinical Trial.

7

Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.

Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr. Ma JD, et al. Among authors: nafziger an. Drug Metab Dispos. 2006 May;34(5):783-5. doi: 10.1124/dmd.105.007831. Epub 2006 Feb 7. Drug Metab Dispos. 2006. PMID: 16467135

8

Comparison of midazolam and simvastatin as cytochrome P450 3A probes.

Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Chung E, et al. Among authors: nafziger an. Clin Pharmacol Ther. 2006 Apr;79(4):350-61. doi: 10.1016/j.clpt.2005.11.016. Epub 2006 Feb 28. Clin Pharmacol Ther. 2006. PMID: 16580903 Clinical Trial.

9

Sex differences in CYP3A activity using intravenous and oral midazolam.

Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN. Chen M, et al. Among authors: nafziger an. Clin Pharmacol Ther. 2006 Nov;80(5):531-8. doi: 10.1016/j.clpt.2006.08.014. Clin Pharmacol Ther. 2006. PMID: 17112809

10

Desirudin dosing and monitoring in moderate renal impairment.

Nafziger AN, Bertino JS Jr. Nafziger AN, et al. J Clin Pharmacol. 2010 Jun;50(6):614-22. doi: 10.1177/0091270009350626. Epub 2009 Nov 13. J Clin Pharmacol. 2010. PMID: 19915180

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters